NASDAQ$EGRX
Eagle Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported second quarter 2021 results with increased revenue and progress in product development.
Eagle Pharmaceuticals reported a strong Q2 2021 with total revenue of $48.1 million, driven by higher product sales of BELRAPZO® and RYANODEX®. The company also announced a licensing agreement for Landiolol and anticipates the commercial launch of vasopressin by year-end.
- Total revenue for Q2 2021 was $48.1 million, compared to $41.9 million in Q2 2020.
- Net income for Q2 2021 was $3.6 million, or $0.28 per basic share and $0.27 per diluted share.
- Adjusted non-GAAP net income for Q2 2021 was $12.4 million, or $0.95 per basic share and $0.93 per diluted share.
- The company announced a licensing agreement for U.S. commercial rights to Landiolol.
Headline financials
Revenue & EPS history
Eagle · Revenue · Quarterly
$48.1M
Revenue by segment
Eagle · $18.2M total across 2 segments · Q4 2022
- BELRAPZO product sales$11M+100.0%60.4%
- RYANODEX product sales$7.2M+18.0%39.6%
Forward guidance
Eagle Pharmaceuticals expects approximately $20-$25 million from combined royalty and milestone revenue next year for TREAKISYM (bendamustine), if TREAKISYM RI formulation is approved
Tailwinds
- Potential for $20-$25 million in royalty and milestone revenue from TREAKISYM.
- PEMFEXY™ launch in February 2022, allowing an initial period of exclusivity.
- Landiolol solidifies hospital and critical care product portfolio.
- Leveraging current sales force for Landiolol with little additional infrastructure costs.
- Pursuing other opportunities to build value for the company.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-0.8%
Avg return
30 days after
55%
22 / 40 earnings
Positive
+75.2%
Q1 2014
Best reaction
-18.8%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2023 | -7.1% | -13.6% | -14.0% | |
| Q2 2023 | -11.8% | -12.2% | -25.9% | |
| Q1 2023 | +6.3% | +12.1% | +0.7% | |
| Q4 2022 | +2.2% | +2.6% | +20.9% | |
| Q3 2022 | +13.4% | +19.2% | +0.9% | |
| Q2 2022 | -18.8% | -16.9% | -28.3% | |
| Q1 2022 | +3.6% | -2.7% | -10.8% | |
| Q4 2021 | +8.9% | +12.5% | +9.2% | |
| Q3 2021 | +1.2% | +0.8% | -10.1% | |
| Q2 2021 | +4.4% | +6.6% | +12.6% | |
| Q1 2021 | -4.7% | +0.5% | -6.7% | |
| Q4 2020 | -11.2% | -4.7% | -7.7% | |
| Q3 2020 | +7.7% | +3.8% | +0.3% | |
| Q2 2020 | -8.3% | -8.7% | -20.6% | |
| Q1 2020 | -4.6% | -3.9% | +12.5% | |
| Q4 2019 | -4.2% | -11.0% | -5.8% | |
| Q3 2019 | -5.5% | -7.5% | -4.3% | |
| Q2 2019 | +3.4% | +4.8% | -0.2% | |
| Q1 2019 | -0.6% | -3.6% | +1.8% | |
| Q4 2018 | +6.1% | -0.1% | +3.4% | |
| Q3 2018 | +3.7% | +5.6% | +2.4% | |
| Q2 2018 | +1.8% | +2.9% | -13.6% | |
| Q1 2018 | -2.7% | -1.3% | -1.3% | |
| Q4 2017 | -14.6% | -19.8% | -22.0% | |
| Q3 2017 | -3.7% | -2.6% | +4.8% | |
| Q2 2017 | +7.1% | +18.8% | +26.5% | |
| Q1 2017 | +0.6% | +0.0% | +9.3% | |
| Q4 2016 | +0.8% | +4.2% | +9.1% | |
| Q3 2016 | +15.2% | +13.7% | +3.7% | |
| Q2 2016 | +18.4% | +28.3% | +28.6% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | -1.5% | — | — | |
| Q3 2015 | +1.3% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2014 | +75.2% | — | — | |
| Q1 2015 | +24.7% | — | — | |
| Q4 2014 | -0.4% | — | — | |
| Q3 2014 | +4.0% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q2 2014 | -0.8% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro